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Huntington’s disease (HD) is caused by a polyglut-
amine tract expansion in huntingtin (HTT). Despite
HTTs ubiquitous expression, there is early and
robust vulnerability in striatum, the cause of which
is poorly understood. Here, we provide evidence
that impaired striatal mTORC1 activity underlies var-
ied metabolic and degenerative phenotypes in HD
brain and show that introducing the constitutively
active form of the mTORC1 regulator, Rheb, into
HD mouse brain, alleviates mitochondrial dysfunc-
tion, aberrant cholesterol homeostasis, striatal
atrophy, impaired dopamine signaling, and increases
autophagy. We also find that the expression of Rhes,
a striatum-enriched mTOR activator, is reduced in
HD patient and mouse brain and that exogenous
addition of Rhes alleviates motor deficits and im-
proves brain pathology in HD mice. Our combined
work indicates that impaired Rhes/mTORC1 activity
in HD brain may underlie the notable striatal suscep-
tibility and thus presents a promising therapeutic
target for HD therapy.
INTRODUCTION
Huntington’s disease (HD) is a fatal autosomal-dominant neuro-
degenerative disease caused by CAG repeat expansion in exon
1 of huntingtin, which encodes the protein huntingtin (HTT) (The
Huntington’s Disease Collaborative Research Group, 1993).
Despite HTT expression in all tissues and brain regions, the stria-
tum demonstrates the most profound and early degeneration.
Mutant HTT (mHTT) negatively affects multiple cellular path-
ways, including mitochondria biogenesis (Cui et al., 2006; Tsu-
nemi et al., 2012), cholesterol homeostasis (Karasinska and
Hayden, 2011; Valenza and Cattaneo, 2011; Valenza et al.,
2005), axonal growth (Li et al., 2001), and synaptogenesis (Mil-
nerwood and Raymond, 2010), all of which may contribute toneuronal dysfunction and loss. These varied phenotypes may
result from disruption of a core component regulating a range
of fundamental biological processes. Identifying such a primary
pathogenic event would facilitate therapeutic development.
Mechanistic target of rapamycin (mTOR) is a serine-threonine
kinase that integrates signals to regulate cell growth and meta-
bolism (Laplante and Sabatini, 2012). mTOR forms 2 distinct
complexes, mTORC1 and mTORC2. Under nutrient-rich condi-
tions, mTORC1 is activated and promotes protein translation
and cell growth. In contrast, nutrient withdrawal inactivates
mTORC1 and initiates macroautophagy (hereafter referred to
as autophagy) as a cell survival mechanism. mTORC1 posi-
tively controls mitochondrial biogenesis (Cunningham et al.,
2007) and regulates lipid homeostasis by controlling cholesterol
synthesis (Peterson et al., 2011; Porstmann et al., 2008). More-
over, in the brain, mTORC1 promotes myelination, axon
growth, and regeneration (Kim et al., 2012; Park et al., 2008;
Sun et al., 2011), and genetic deletion of the Ras homolog en-
riched in brain (Rheb), a key activator of mTORC1, causes
decreased cortical thickness and defective myelination (Zou
et al., 2011).
In the striatum Ras homolog enriched in the striatum (Rhes)
serves as a key activator of mTORC1 (Subramaniam et al.,
2012). Genetic knockout of Rhes reduces mTORC1 activity
and attenuates adverse responses to L-DOPA-induced dyski-
nesia (Subramaniam et al., 2012). Additionally, Rhes facilitates
SUMOylation (Subramaniam et al., 2009), a process implicated
in HD pathogenesis (Steffan et al., 2004). In vitro, Rhes promotes
SUMOylation of mHTT to induce cytotoxicity (Subramaniam
et al., 2009), and reducing exogenously added Rhes with
siRNAs increased survival of cells transfected with mHTT frag-
ments (Lu and Palacino, 2013; Seredenina et al., 2011). In vivo,
genetic ablation of Rhes protects against neurotoxin-induced
striatal lesions (Mealer et al., 2013) and transiently delays motor
symptom onset in R6/1 HD mice (Baiamonte et al., 2013).
Because Rhes is highly expressed in the striatum (Spano et al.,
2004), it has been proposed that Rhes-mHTT interactions may
underlie the prominent striatal degeneration in HD.
However, other data call to question a pathogenic role for
Rhes in HD. Rhes levels are reduced in HD patient caudate nu-
cleus (Hodges et al., 2006), and Rhes ablation in R6/1 HDmodelsNeuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc. 303
Figure 1. mTORC1 Activity Is Reduced in
HD Human and Mouse Striatum
(A) Immunoblotting of mTOR, Rictor, Raptor, and
mTORC1 activity (pS6) showed reduced mTORC1
activity in the striatum of patients with HD (n = 10;
see Figure S1A for expanded series) compared to
unaffected individuals (n = 6). b-actin was used as
a loading control. Data represent mean ± SEM.
***p < 0.001, Student’s t test.
(B) Immunoblotting of mTOR, Rictor, Raptor, and
pS6 from 6-week-old N171-82Q and WT mouse
striatal lysates. b-actin was used as a loading
control. Densitometry analyses for (A) and (B)
revealed reduced pS6 levels in HD patient (n = 10)
versus controls (n = 6) and 6-week-old N171-82Q
mice (n = 4) compared to age- and sex-matched
WT littermates (n = 4). Data represent mean ±
SEM.*p < 0.05; ***p < 0.001, Student’s t test.does not prevent brain degeneration (Baiamonte et al., 2013).
Furthermore, Rhes KO mice develop brain atrophy and behav-
ioral abnormalities resembling those found in HD mice (Baia-
monte et al., 2013; Spano et al., 2004). In addition, Rhes
promotes autophagy (Mealer et al., 2014), a well-established
protective mechanism in HD. Therefore, given the critical func-
tion of Rhes in mediating striatal mTORC1 signaling, we hypoth-
esized that a concomitant loss of Rhes and mTORC1 activity
contributes to the early striatal pathology in HD and that
enhancing mTORC1 function, through upregulation of Rheb or
Rhes, would be neuroprotective.304 Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc.To test this hypothesis we acutely
modulated Rhes and mTORC1 activity in
adult striata of HD transgenic mice. We
found beneficial effects with mTORC1
activation, including improved mHTT-
associated metabolic phenotypes and
reversal of striatal atrophy. Consistently,
restoring mTORC1 activity or Rhes levels
in vivo was protective. Further, we
showed that the neuroprotective property
of Rhes is dependent on its GTPase
activity, which is required for activating
mTORC1 but independent of SUMOyla-
tion-related activity. Collectively, these
data suggest that impaired Rhes/
mTORC1 activity is relevant to the
notable striatal pathogenesis in HD and
suggest that impaired mTORC1 function
may represent a fundamental mechanism
underlying the complex disease pheno-
types in HD.
RESULTS
mTORC1 Activity Is Reduced in the
Striatum of HD
As a first test of our hypothesis, we
examined mTORC1 activity in HD brain.We found that mTORC1 activity is reduced in striatal tissues
from HD patients and N171-82Q mice as detected by reduced
phosphorylation of ribosomal protein S6 (pS6), an established
marker of mTORC1 activity (Figure 1A; Figures S1A and S1B
available online). In HD mice, mTORC1 activity is impaired at
6 weeks of age, prior to the onset of neurological symptoms
(Figure 1B). The reduced mTORC1 activity is not associated
with reduced expression of mTOR or components of the
mTOR complex (e.g., Rictor and Raptor) (Figures 1A and 1B;
Figure S1A). We next engineered adeno-associated viruses
(AAVs), which transduce striatal neurons (Figure S2A) (McBride
Figure 2. Activation of mTORC1 Pathway
Corrects Metabolism-Related Deficits in
HD Mice
(A) Western blot shows increased pS6 and
DARPP-32 immunoreactivity in N171-82Q mice
treated with unilateral injection of AAV.caRheb,
compared to control untreated mice. Mice were
injected at 7 weeks of age and striatal lysates
harvested at 10 weeks of age. Right, densitometry
quantification of DARPP-32 immunoreactivity
(n = 4 mice per group; *p < 0.05, one-way ANOVA
with Tukey’s post hoc test).
(B) Quantitative real-time PCR (RT-qPCR) analysis
of PGC1-a in striatal homogenates from 10-week-
old N171-82Q mice treated with unilateral injec-
tion of AAV.caRheb at 7 weeks of age. Striatal
lysates from uninjected contralateral hemispheres
served as internal controls (n = 8 per group).
(C–G) RT-qPCR analysis of ROS detoxifying
genes in striatal homogenates from 10-week-old
N171-82Q andWTmice after unilateral injection of
AAV.caRheb at 7 weeks of age. Lysates from un-
injected contralateral hemispheres served as in-
ternal controls (n = 8 per group). All genes were
normalized to endogenous b-actin. Data repre-
sent mean ± SEM. C = Control. *p < 0.05; **p <
0.01; ***p < 0.001, Student’s t test.et al., 2008), to express Rheb, a well-established positive
regulator of mTORC1 (Laplante and Sabatini, 2012). In this
manner, we can acutely enhance mTORC1 activation in vivo.
We used a constitutively active Rheb mutant (caRheb; S16H)
previously shown to activate mTORC1 signaling in mouse
brain (Kim et al., 2012; Zou et al., 2011). Unilateral injection
of AAV.caRheb into N171-82Q mouse striata markedly induced
mTORC1 activity as indicated by increased pS6 at 3 weeks
postinjection (Figure 2A). Selective reduction of DARPP-32
levels, a fundamental component of dopamine signaling in
medium spiny neurons (MSNs), is an indicator of pathological
progression in HD mouse and human brains (Bibb et al.,
2000; Hodges et al., 2006). AAV.caRheb transduction pro-
moted a 33% increase of DARPP-32 levels in N171-82Q
mouse striata compared to contralateral uninjected tissue
(Figure 2A). Moreover, AAV.caRheb upregulated expression
of the mitochondrial-transcriptional regulator, PPARg coactiva-
tor 1a (PGC1-a) (Figure 2B), a master regulator of mitochon-
drial biogenesis that when increased improves mitochondrialNeuron 85, 303–315,function and motor deficits in HD
models (Cui et al., 2006; Tsunemi
et al., 2012). Consistent with increased
mitochondria activity, the levels of reac-
tive oxygen species (ROS) detoxifying
genes SOD2, cyt-c, and ANT1 were
also increased in AAV.caRheb-treated
brains (Figures 2C–2F). Glutathione
peroxidase, a recently identified neuro-
protective antioxidant enzyme in HD
model organisms (Mason et al., 2013),
selectively increased in HD brains aftercaRheb transduction (Figure 2G). The improved profile could
not be explained by an indirect effect of virus injection or
downregulation of the mHTT transgene; similar results were
obtained when AAV.caRheb-injected brains were compared
to AAV.eGFP-treated brains, and caRheb did not affect
mHTT transgene expression (Figures S2B–S2H).
We next performed in vitro studies and treated striatal cells
that express expanded (Q111) and normal (Q7) Htt (Trettel
et al., 2000) with an ATP-competitive inhibitor of mTOR, Torin1.
Torin1 potently inhibits mTOR functions, including those that are
resistant to inhibition by rapamycin (Thoreen et al., 2009). Torin1
treatment reduced pS6 and p-4E-BP1 levels as well as DARPP-
32 expression in Q7 and Q111 cells (Figure S3A). Torin1 also
repressed PGC1-a, the PGC1- a-regulated genes cAMP
response element-binding protein (CREB), and transducer of
regulated CREB 1 (TORC1) (Figures S3A and S3B). Together,
our in vitro and in vivo results indicate that mTORC1 regulates
PGC1-a and PGC1-a regulated metabolic genes in the setting
of wild-type (WT) and mHTT alleles.January 21, 2015 ª2015 Elsevier Inc. 305
Figure 3. mTOR Regulates Cholesterol
Biosynthetic Pathway Genes in HD Mice
Striata
(A and B) WT (Q7) and mutant (Q111) striatal cells
grown in normal media were treated with 250 nM
Torin1 or DMSO (control). Total cell extracts were
obtained 24 hr after treatment. Gene expression
levels of HMGCR and HMGCS1 were normalized
to endogenous b-actin.
(C–F) RT-qPCR analysis of lipogenic genes from
striatal homogenates of 10-week-old N171-
82Q and WT mice after unilateral injection of
AAV.caRheb at 7 weeks of age. Lysates from
uninjected contralateral hemispheres served as
internal controls (n = 8 per group). All genes were
normalized to endogenous b-actin. Data represent
mean ± SEM. C = Control. *p < 0.05; **p < 0.01;
***p < 0.001, Student’s t test.mTORC1 Controls Lipogenic Gene Expression in HD
Brains
We next determined whether impaired mTORC1 activity under-
lies other HD-specific metabolic pathway alterations. Aberrant
cholesterol biosynthesis has been observed in HD mouse and
human brains (Karasinska and Hayden, 2011; Valenza and
Cattaneo, 2011). The expression of genes required for lipid
biosynthesis is controlled by nuclear transactivation of sterol
regulatory element-binding proteins. mHTT has been reported
to inhibit nuclear translocation of SREBP in cells and HD mice,
which may contribute to dysfunctional cholesterol synthesis
(Valenza et al., 2005). mTORC1 also regulates SREBP transac-
tivation (Peterson et al., 2011; Porstmann et al., 2008). To
determine if reducing mTORC1 activity alters cholesterol syn-
thesis in the setting of HD, we applied Torin1 to cultured Q7
or Q111 striatal cells. Torin1 reduced expression of the SREBP
target genes HMG-CoA reductase (HMGCR), the rate-limiting
enzyme in cholesterol synthesis and HMG-CoA synthase 1
(HMGCS1) in both mutant and normal cell lines (Figures 3A
and 3B).
InN171-82Qmice, HMGCR is significantly reduced (Figure 3C)
compared to controls, similar to that found in HD patient brains
(Hodges et al., 2006). AAV.caRheb normalized HMGCR levels
and also increased expression of sterol biosynthesic enzymes:
HMGCS1, lanosterol 14a-demethylase (CYP51), and 7-dehydro-
cholesterol reductase (DHCR7) (Figures 3C–3F and S3C–S3F).
Similar to our in vitro findings, mTOR’s regulation of striatal
lipogenic gene expression is independent of the state of poly-
glutamine expansion in HTT, as AAV.caRheb also increased
expression of these genes in WT striata as well (Figures 3C–
3F). Although the reduction of HMGCR gene expression is mild306 Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc.in N171-82Q mice (transgene expressed
from prion promoter), reduced expres-
sion of HMGCR, HMGCS1, DHCR7, and
CYP51 are observed in HD human and
other mouse models (Hodges et al.,
2006; Valenza et al., 2005). Together,
our results indicate that mTORC1 pro-
motes lipogenic gene expression in thestriatum and suggest that impaired mTORC1 activity may
contribute to reduced lipogenic gene expression in HD.
mTORC1 Enhances Pathways Implicated in mHTT
Clearance
mTORC1 activity is generally associated with antagonizing
autophagy induction, although autophagy can occur through
mTORC1-dependent and -independent pathways. With rele-
vance to HD, basal autophagic activity is critical for maintaining
neuronal survival and promoting aggregate clearance (Jeong
et al., 2009; Ravikumar et al., 2004; Yamamoto et al., 2006). As
such, we next examined the effects of mTORC1 activation on
autophagy in AAV.caRheb-treated HD mouse striata. We found
increased basal levels of the autophagosome-membrane-asso-
ciated protein LC3-II in N171-82Q mice compared to WT mice
(Figure S4). AAV.caRheb treatment increased levels of LC3-II
(Figure 4A) and Beclin-1, a protein necessary for autophagy
induction (Figure 4B). To distinguish between enhanced auto-
phagy and impairment of autophagolysosomal maturation, elec-
tronmicroscopy (EM) was used to quantify the relative number of
autophagosomes and autolysosomes in brains of mice treated
with AAV.caRheb in one hemisphere or AAV.eGFP in the other
hemisphere. While the autophagosomes/autolysosome ratio
was similar between hemispheres, both autophagosomes and
autolysosomes were increased with AAV.caRheb treatment
compared to the control-treated contralateral sides (Figure 4C),
suggesting that autophagy is activated in the setting of increased
mTORC1 activity in vivo. We also noted that control-treated
(AAV.eGFP) N171-82Q mice brain was depleted of electron-
dense endoplasm granular mass and cytoplasmic organelles
(Figure 4D), a phenotype similar to the striatal pathology induced
Figure 4. AAV.caRheb Increases Basal Autophagy in N171-82Q Mice
(A and B) Biochemical assessment of autophagy (LC3 and Beclin1) in striatal lysates from N171-82Q mice after unilateral injection of AAV.caRheb at 7 weeks of
age. Striata were harvested 3 weeks postinjection. Uninjected contralateral striata serve as internal controls (n = 6 mice per group). Representative western blots
and densitometry analysis revealed increased LC3II and Beclin1 levels in AAV.caRheb-treatedN171-82Qmice striata. b-actin was used as a loading control. Data
are mean ± SEM.**p < 0.01; Student’s t test.
(C) Left panels: representative photomicrographs of an autophagosome (arrow) and an autolysosome (double arrow). Scale bar is 0.5 mm. Right panel: frequency
of autophagosomes and autolysosomes detected in striatal neurons fromAAV.eGFP- and AAV.caRheb-treated N171-82Qmice (threemice examined per group;
seven to ten cells/hemisphere/animal). Ratio indicates number of autophagosome or autolysosome over total number of cells counted.
(D) Ultrastructural TEM analysis of striatal sections from N171-82Q mice after AAV.eGFP or AAV.caRheb injections into opposite hemispheres (n = 3 mice per
group). Left panel: a representative photomicrograph of striatal neurons from control treated striata shows electron-lucent cytoplasm, devoid of endoplasm
granular mass and organelles. Right panel: AAV.caRheb-treated neurons show normal cytoplasm enriched with organelles and endoplasm granular mass. Scale
bar is 5 mm.by nucleolar stress (Kreiner et al., 2013). Conversely, cells in
AAV.caRheb-treated hemispheres showed enriched electron-
dense cytoplasmic organelles.
Recent work suggests that autophagic/proteasomal degra-
dation of mHTT occurs through posttranslational modifications
(Jeong et al., 2009; Jia et al., 2012; O’Rourke et al., 2013;
Thompson et al., 2009). For example, the SUMO E3 ligase
PIAS1 increases mHTT aggregate formation by promoting
SUMO2 conjugation to mHTT in cell models, and reducing
the PIAS1 ortholog in Drosophila expressing the mHTT protein
is protective (O’Rourke et al., 2013). We found that SUMO2
levels were elevated in 14-week-old N171-82Q mouse striatum
and that AAV.caRheb repressed PIAS1 and SUMO2 expres-
sion in both N171-82Q mice and WT control littermates
(Figures 5A and 5B). We also examined IkB kinase (IKK), a ki-
nase that induces mHTT degradation and targets mHTT for
clearance by the proteasome and lysosome (Thompsonet al., 2009). Endogenous IKK-related genes (Ikbkb, Ikbkap,
and Ikbke) were reduced in N171-82Q mouse striata, and
AAV.caRheb restored their expression (Figures 5C–5E). Addi-
tionally, HDAC4 is an important regulator of mHTT aggregate
formation, and reduction of HDAC4 reduces cytoplasmic ag-
gregates, improves neuronal function, and extends the life
span of HD mice (Mielcarek et al., 2013). Here, we found that
AAV.caRheb transduction reduced HDAC4 expression in
N171-82Q mouse striata (Figure 5F). HTT fragment-containing
aggregates are few and inconsistent in striatum but robust in
hippocampus in N171-82Q mice. Therefore, we tested aggre-
gate burden in the hippocampus. AAV efficiently transduces
hippocampal neurons (Figure S5), and AAV.caRheb-injected
animals showed significantly reduced mHTT aggregate load
compared to AAV.eGFP-injected mice (Figure 5G), consistent
with the observed effects of AAV.caRheb on genes involved
in mHTT clearance.Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc. 307
Figure 5. mTORC1 Regulates Genes
Involved in mHTT Aggregate Clearance
(A–F) RT-qPCR analysis of genes from striatal
homogenates of 10-week-old N171-82Q and WT
mice after unilateral injection of AAV.caRheb at
7 weeks of age. The uninjected contralateral side
served as an internal control (n = 8 per group).
(A and B) Expression of genes implicated in the
SUMO modification of mHTT.
(C–E) Expression of IKK-related genes (Ikbkb,
Ikbkap, and Ikbke).
(F) Expression of HDAC4. All genes were normal-
ized to endogenous b-actin. Data represent
mean ± SEM. C = Control. *p < 0.05; **p < 0.01;
***p < 0.001, Student’s t test.
(G) Left panels, immunohistochemical staining of
N171-82Qmouse hippocampi with EM48 2 weeks
after a single unilateral injection of AAV.caRheb
and AAV.eGFP into the hippocampus of 10-week-
old N171-82Q mice (n = 4 per treatment group;
Scale bar: 50 mm). Right panel, AAV.caRheb
reduced EM48-positive aggregates. Arrows:
Em48-positive aggregates. Data represent
mean ± SEM. *p < 0.05. Student’s t test.Enhanced mTORC1 Activity Rescues Striatal Atrophy
and Improves Motor Phenotypes in HD Mice
N171-82Q mice display pronounced striatal atrophy with pre-
served MSN numbers (Cheng et al., 2011; Schilling et al.,
1999). To examine howmTORC1 activity impacts striatal volume
in diseased brain, we performed unilateral AAV.caRheb injection
into the striata of 11-week-old N171-82Q mice, an age by
which there is measurable striatal atrophy (Cheng et al., 2011),
and compared the treated hemisphere with the untreated side.
AAV.caRheb positively impacted MSN cell size and striatal
volume compared to untreated contralateral hemispheres (Fig-
ures 6A–6C). To confirm that caRheb acts through mTORC1,
we administered RAD001, a known mTORC1 inhibitor (Fox
et al., 2010). RAD001 treatment reversed the morphological ef-
fects of caRheb and attenuated S6 phosphorylation (Figures
6A–6C, S6A, and S6B). Additionally, we found that 2 weeks of
RAD001 treatment in the absence of caRheb caused a mild
but significant exacerbation of MSN atrophy in N171-82Q mice
(Figures 6A and 6B). These results suggest that AAV.caRheb308 Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc.promotes MSN growth or preserves
MSN size through the mTORC1 pathway
and that impairing mTORC1 in vivo exac-
erbates this phenotype.
Impaired striatal dopamine circuitry is
associated with motor symptoms in HD
mice (Bibb et al., 2000; Johnson et al.,
2006). Therefore, to determine the func-
tional impact of AAV.caRheb on dopa-
mine pathways, we unilaterally injected
N171-82Q mice and subjected them to
amphetamine-induced rotational tests.
Amphetamine triggers dopamine release
and induces rotational behavior in mice if
there is imbalanced dopamine signalingin one hemisphere versus the other. For this, we coinjected
AAV expressing mHTT (AAV.mHTT) into 6-week-old WT mice
with either AAV.caRheb or control virus (AAV.eGFP). Unilateral
injection of AAV.mHTT/AAV.eGFP caused ipsilateral rotation
toward the injected side, an indication of mHTT-induced toxicity
(Figure 6D). In contrast, coinjection of AAV.caRheb with
AAV.mHTT did not induce ipsilateral rotation; instead, mice dis-
played contralateral rotations (Figure 6D). Consistent with the
behavioral results, injection of AAV.mHTT/eGFP causedMSN at-
rophy compared to untreated contralateral striatum whereas co-
injection of AAV.caRhebwithAAV.mHTTpreventedMSNatrophy
(Figure 6E). Thus, enhancing mTORC1 activity benefits mHTT-
driven neuronal atrophy and dopamine pathway impairment.
Exogenous Addition of Rhes, a Striatum-EnrichedmTOR
Activator, Rescues mHTT-Associated Disease
Phenotypes in HD Transgenic Mice
In the striatum, mTOR is predominantly regulated by a striatal-
enriched GTPase protein, Rhes (Subramaniam et al., 2012). Prior
Figure 6. mTORC1 Promotes MSN Growth and Counteracts mHTT-Induced Motor Phenotypes
(A) Immunohistochemical staining of MSNs with anti-DARPP-32, 2 weeks after a single unilateral injection of AAV.caRheb into the striatum of 11-week-old N171-
82Q mice. Mice were given vehicle or RAD001 for 2 weeks.
(B and C) Quantification of MSN cell area and striatal volumes from tissues of animals treated as in (A) (n = 4 per treatment group; mean ± SEM).
(D) WT mice injected unilaterally with AAV.mHTT/AAV.eGFP or AAV.mHTT/AAV.caRheb at 6 weeks of age. When tested 4 weeks postinjection, AAV.mHTT/
AAV.eGFP induced ipsilateral rotational behavior in response to amphetamine. Coinjection of AAV.caRheb altered AAV.mHTT-induced ipsilateral rotation
following amphetamine administration, with mice displaying contralateral rotation (n = 4 per treatment group). *p < 0.05; **p < 0.001; ***p < 0.001, Student’s t test.
Scale bars: 100 mm ([A]–[D]).
(E) Left panels, immunohistochemical staining of MSNs with anti-DARPP-32 of sections from AAV.mHTT/AAV.eGFP- or AAV.mHTT/AAV.caRheb-injected mice
from (D). The contralateral uninjected hemisphere is shown as control. Right panels, quantification of MSN area expressed as percentage of uninjected
contralateral striata.*p < 0.05, Student’s t test. Scale bars: 50 mm.in vitro studies imply a toxic role of Rhes in HD (Subramaniam
et al., 2009), but its disease relevance in vivo is unclear.We found
that Rhes levels were reduced in HD human and mouse striata
(Figures 7A and S7A). Rheb levels are not reduced (Figure S7B).
Notably, Rhes is significantly reduced prior to the onset of neuro-
logical symptoms; 6-week-old N171-82Q mice have 73% of WT
Rhes levels even though clinical symptoms are not evident until
12–14 weeks of age (Figures 7A and S7C). We therefore investi-
gated how enhancing Rhes levels impacts disease phenotypes.
As the N-terminal fragment of mHTT was previously shown to
interact with Rhes and confer cytotoxicity in vitro, the N171-
82Qmodel is ideal for testing this question in vivo (Subramaniam
et al., 2009). If Rhes is a critical mediator of HD toxicity, acute
overexpression of Rhes in N171-82Qmouse striata would be ex-
pected to exacerbate disease phenotypes. AAVs expressing
Rhes (AAV.Rhes) were injected into 7-week-old N171-82Qmice and WT littermates. In contrast to what was expected
from earlier in vitro work, but consistent with our findings on
mTORC1 activation by Rheb, Rhes overexpression improved
motor function in N171-82Q mice compared to saline-treated,
disease littermates as determined by rotarod testing at 14 and
18 weeks of age (Figure 7B). In addition, after unilateral injection,
AAV.Rhes significantly increased MSN cell size compared to
control-treated contralateral hemispheres (Figures 7C). Similar
to Rheb, AAV.Rhes upregulated expression of the mitochon-
drial-transcriptional regulator, PGC1-a (Figure 7D).
In cell-based assays, Rhes enhances mHTT toxicity by pro-
moting SUMOylation of mHTT (Subramaniam et al., 2009). To
ascertain if the observed disease-modifying effects of Rhes
in vivo are via themTORC1 or SUMOylation pathways, we gener-
ated AAVs that express RhesS33N (AAV.RhesS33N), a Rhes
mutant with abolished GTPase activity and reduced mTORC1Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc. 309
Figure 7. Intrastriatal Rhes Overexpression Improves Disease Phenotypes in N171-82Q Mice
(A) RT-qPCR analysis of endogenous Rhes levels from striatal lysates of unaffected individuals (Ctl, n = 4) and HD patients (n = 10), and 6-week-old N171-82Q
(n = 5) and WT (n = 4) littermates. Data represent mean ± SEM. *p < 0.05; ***p < 0.001, Student’s t test.
(B) Rotarod assessment of N171-82Q and WT mice after bilateral injection of AAV.Rhes, AAV.RhesS33N, or saline into the striatum at 7 weeks of age (n = 10–14
mice per group at 14 weeks of age; n = 6–13mice per group at 18 weeks of age). Rotarod data from three consecutive days at 14 and 18 weeks of age are shown
as latency to fall. Saline- and AAV.RhesS33N-injected N171-82Q mice performed significantly worse compared to AAV.Rhes-injected N171-82Q mice on the
rotarod at 14 and 18 weeks of age. NS, not statistically significant. Data represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001, one-way ANOVA with Tukey’s
post hoc test.
(C) DARPP-32 staining and quantification of MSN area of N171-82Q mice striatal tissue sections after unilateral injection of AAV.Rhes and contralateral injection
of AAV.GFP at 7 weeks of age. Tissues were harvested at 19 weeks of age (n = 3 mice/group; GFP = 245 cells; Rhes = 251 cells). Data represent mean ± SEM.
***p < 0.001, Student’s t test. Scale bars: 50 mm.
(D) qPCR analysis of PGC-1a in striata fromAAV.Rhes- or saline-treated N171-82Q andWTmice (n = 6–9 per group) harvested at the end of the study (19weeks of
age). C = Control. *p < 0.05, Student’s t test.activation but intact SUMOylation modulatory activity (Sub-
ramaniam et al., 2009, 2012). Following striatal injections,
AAV.RhesS33N-treated N171-82Q mice showed reduced
mTORC1 activity compared to N171-82Q mice injected with
AAV.Rhes (Figure S8). AAV.RhesS33N failed to modify motor
deficits in N171-82Q mice, which performed similarly to con-
trol-treated N171-82Q mice (Figure 7B). Notably, Rhes S33N
does not cause further behavioral exacerbation, as one would
predict based on prior in vitro observation (Subramaniam et al.,
2009). Collectively, these data suggest that Rhes rescues HD
behavioral deficits in part via mTORC1 activation.
DISCUSSION
Cumulatively, we show that impaired mTORC1 activity is up-
stream of various phenotypic changes associated with HD and
may underlie the metabolic and degenerative phenotypes. We
find that mTORC1 activation promoted energy metabolism,310 Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc.autophagy, and striatal cell function in HD mice. Consistent
with a neuroprotective role of mTORC1, we find that Rhes, a
striatum-enriched mTOR activator, is reduced in HD patient
brains and HD mouse models prior to onset of neurological
symptoms. Also, exogenous Rhes addition alleviated motor def-
icits and brain pathology in HD mice. Notably, the ability to pro-
mote striatal cell growth and function in symptomatic HD mice
supports the notion that there is plasticity in mHTT-laden neu-
rons (Yamamoto et al., 2000) and highlights the possibility of re-
verting striatal atrophy after disease onset through mTORC1
activation. Because mHTT has an increased propensity to bind
Rhes (Subramaniam et al., 2009) and mTOR (Ravikumar et al.,
2004), it is possible that a concomitant loss of Rhes and mTOR
function by mHTT may render the striatum more vulnerable to
early degeneration in HD (Figure 8). Given that striatal volume
is a strong predictor of disease progression in HD patients (Tab-
rizi et al., 2013), therapies that restore striatal mTORC1 activity to
normal levels may alleviate disease.
Figure 8. ProposedMechanism throughwhich ImpairedmTORCon-
tributes to Complex Disease Phenotypes in HD
Under normal physiological condition, mTOR regulates varied biological pro-
cesses that are crucial for neuronal function and survival. In HD,mHTT disrupts
mTORC1 function by direct interaction with mTOR, causing neuronal
dysfunction by negatively impacting multiple pathways. In the striatum, mHTT
further impairs mTORC1 activity by interfering with Rhes, a striatum-enriched
mTOR regulator. Thus, a concomitant loss of Rhes and mTORC1 activity may
render striatal tissue vulnerable to early degeneration in HD.A key disease mechanism by which mHTT interferes with en-
ergy production is repression of PGC-1a activity, whose expres-
sion is reduced in human caudate and HD transgenic mouse
striata (Cui et al., 2006; Hodges et al., 2006; Tsunemi et al.,
2012). Reduced PGC-1a levels may also sensitize HD brains to
oxidative stress as dopaminergic neurons in PGC-1a KO mice
are vulnerable to MPTP-mediated oxidative damage (St-Pierre
et al., 2006). Restoring brain PGC-1a expression ameliorates
striatal atrophy in R6/2 HD mice (Cui et al., 2006), and improves
motor phenotypes in the N171-82Q and R6/2 HDmouse models
(Cui et al., 2006; Tsunemi and La Spada, 2011). Our finding that
mTOR is a positive regulator of PGC-1a activity in HD mouse
brains provides a therapeutic target for enhancing PGC-1a activ-
ity and a potential mechanism by which PGC-1a activity may be
impaired.
At first blush, these datamay appear to contradict the conven-
tional view in the HD field indicating that mTORC1 inhibition is
protective (Ravikumar et al., 2004; Roscic et al., 2011). Inhibition
of mTORC1 by systemic delivery of rapamycin attenuates dis-
ease phenotypes in Drosophila and N171-82Q HDmice (Raviku-
mar et al., 2004). It is possible, however, that the behavioral
improvements induced by rapamycin may reflect the beneficial
effects on skeletal muscle rather than mTORC1 inhibition in the
brain. In line with this, in R6/2 HD mice treated with rapamycin,
rotarod improvement is transient and associated with acceler-
ated weight loss and enhanced brain atrophy (Fox et al., 2010).
Interestingly, mTORC1 activity is abnormally elevated in R6/2
mouse skeletal muscles (She et al., 2011). Together with our
data, these findings support the notion that restoring balanced
mTORC1 activity is critical and raise the interesting point that
there can be tissue-specific effects of mHTT on mTOR activity;
unlike skeletal muscle, brain mTORC1 activity is already
impaired in HD.
The finding that mTORC1 enhancement is neuroprotective
also provides a mechanistic basis for earlier studies supportinga role for various agents shown to be therapeutic in HD models.
For example, restoring BDNF-TrkB signaling has well-estab-
lished neuroprotective effects in several preclinical HD models
(Jiang et al., 2013; Simmons et al., 2013; Xie et al., 2010; Zuccato
et al., 2001). A physiological consequence of this signaling
cascade is mTORC1 activation (Troca-Marı´n et al., 2011; Zhou
et al., 2010). Moreover, an RNAi screen identified Lkb-1 as a
potent disease modifier in cell and Drosophila HD models
(Schulte et al., 2011). Lkb-1 is a tumor suppressor that negatively
regulates mTORC1 (Shaw et al., 2004). Suppressing Lkb-1
improved mHTT-induced dysmorphic neurite growth in primary
neurons and rescued lethality and neurodegenerative pheno-
types in Drosophila expressing a mHTT allele (Schulte et al.,
2011). Together, these results are consistent with our view that
rebalancing mTORC1 activity is beneficial in HD.
Autophagy is essential for cell homeostasis and protein clear-
ance (Wong and Cuervo, 2010). We find that mTORC1 activation
stimulates autophagic activity in HD mouse brains and alters
expression of genes implicated in promoting mHTT degradation
(PIAS1, SUMO2, IKK, and HDAC4). These results may be sur-
prising as mTORC1 is generally considered inhibitory to auto-
phagy. However, recent evidence demonstrate that autophagy
can occur under mTOR-stimulated conditions (Narita et al.,
2011), and under prolonged starvation conditions, reactivation
of mTOR promotes formation of lysosomes, which are required
for sustained autophagy (Yu et al., 2010). We suspect that
enhanced basal or quality control autophagy is a necessary
response to cell growth andmetabolic activity and, unlike starva-
tion-induced autophagy, is consistent with mTORC1 activation.
Although the precise mechanism by which mTORC1 induces
autophagy is unclear, we found mTORC1 enhancement
increased beclin1 levels, an essential component involved in
autophagic vesicle nucleation. Interestingly, overexpression of
beclin 1 induces autophagic clearance of mHTT aggregates
(Shoji-Kawata et al., 2013). Additionally, we find that mTORC1
upregulates expression of IKK, a known autophagy inducer
that promotes mHTT degradation (Thompson et al., 2009).
Further, stimulation of IGF1/Akt signaling, which in-turn activates
mTORC1, induces mHTT phosphorylation and targets mHTT
degradation (Humbert et al., 2002; Yamamoto et al., 2006).
Cumulatively, the data show that varied mechanisms for mHTT
degradation are interrelated and controlled by mTORC1 activity.
The striatum-enriched protein, Rhes, is proposed to cause
striatal degeneration by promoting SUMOylation of mHTT;
siRNA knockdown of SUMO1 abolishes Rhes-mediated cyto-
toxicity in vitro (Subramaniam et al., 2009). Contrary to the po-
tential toxic role of Rhes, we find that Rhes addition improves
neuropathological and motor phenotypes in HD mice and that
this neuroprotective property of Rhes requires its GTPase activ-
ity. This is in contrast to the in vitro condition, where the GTPase
activity of Rhes is not involved withmHTT-mediated cytotoxicity.
Interestingly, we find that reducing Rhes levels in vivo causes
compensatory upregulation of SUMO1 in HD mouse striata
(data not shown). This is consistent with the observation that
SUMO1- and SUMO2-modified proteins accumulate in HD post-
mortem human brains (O’Rourke et al., 2013). Additionally, over-
expressing the GTPase-deficient but SUMOylation-intact Rhes
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mice as one would predict based on prior in vitro results (Subra-
maniam et al., 2009), implying that the in vivo modulators of MSN
toxicity is distinct from that in an isolated culture system.
Consistent with a cytoprotective role of Rhes, we recently re-
ported that siRNA knockdown of Rhes exacerbates striatal atro-
phy and behavioral phenotypes in transgenic HDmice (Lee et al.,
2014). On the other hand, other work showed that crossing Rhes
KO mice with R6/1 mice delayed rotarod deficits (Baiamonte
et al., 2013). However, genetic deletion of Rhes does not prevent
striatal atrophy in the R6/1mice, and Rhes KOmice demonstrate
severe brain degeneration similar to HD mice (Baiamonte et al.,
2013). Further, Rhes levels are reduced in HD patients and HD
mouse model striata, with symptomatic HD patients showing a
striking 83% reduction of striatal Rhes compared to unaffected
individuals (Figure 7A). Rhes has recently been shown to pro-
mote autophagy (Mealer et al., 2014) and regulate intracellular
iron homeostasis (Choi et al., 2013). Therefore, restoring rather
than reducing Rhes may be beneficial in HD brains.
The finding that normalizing mTORC1 activity improves HD
phenotypes may have broad therapeutic implication for neuro-
logical diseases with deregulated mTOR activity. For instance,
neurodevelopmental disorders such as fragile X mental retarda-
tion and autism are generally associated with hyperactive
mTORC1 activity; suppressing mTORC1 in these conditions im-
proves disease phenotypes (Bhattacharya et al., 2012; Tsai
et al., 2012). In contrast, in the case of amyotrophic lateral scle-
rosis (ALS) where neuronal mTORC1 activity is reduced, stimula-
tion of mTORC1 counteracts the degenerative process (Saxena
et al., 2013). Thus, restoring the homeostatic level of mTORC1
function may broadly benefit neurological diseases.
In summary, our study provides new insight into the intercon-
nectivity of complex pathological phenotypes in HD, which
converge on the mTORC1 pathway, and, together with prior
work in other neurodegenerative disease fields, highlights the
observation that the extent of mTORC1 activation must be care-
fully controlled for therapeutic utility. While reducing the expres-
sion of the mHTT in the brain would be a direct way to rescue
mTORC1 activity in the setting of HD, a rebalance of mTORC1
activity by regulated gene therapy or with small molecules that
disrupt Rhes-mHTT binding may be of therapeutic benefit.
EXPERIMENTAL PROCEDURES
Animals
All animal protocols were approved by the University of Iowa Animal Care and
Use Committee. N171-82Q mice were from Jackson Labs (Bar Harbor) and
maintained on B6C3F1/J background. Hemizygous and age-matched WT
littermates were used for the indicated experiments. Mice were housed in a
controlled temperature environment on a 12 hr light/dark cycle. Food and
water were provided ad libitum. For pharmacological studies, RAD001 was
obtained from LC Laboratories, diluted to 2 mg/ml in 2% DMSO, and stored
at 20C. Freshly thawed vehicle and RAD001 (30 mmol/kg) were given three
times per week (Monday, Wednesday, and Friday) for 2 weeks by gavage as
described previously(Fox et al., 2010). Mice were sacrificed 24 hr after the
last dose.
Plasmids and AAVs
AAV vectors serotype 1 (AAV2/1) were used for this study. Rhes and Rheb
cDNA sequences were amplified from a mouse striatum cDNA library. A
Flag epitope was cloned 30 for western blot assay. GTPase-inactive Rhes312 Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc.mutant (RhesS33N) and constitutively active Rheb mutant (caRheb;S16H)
were generated by QuikChange site-directed mutagenesis (Agilent Technol-
ogy). Primers for mutagenesis used the QuikChange Primer Design Program
(http://www.genomics.agilent.com). Rhes, RhesS33N, and caRheb se-
quences were cloned into AAV vectors downstreamof the chicken b-actin pro-
moter. AAV.Rhes and AAV.RhesS33N vectors also express enhanced GFP
(eGFP) under the control of an IRES sequence. N-terminal myc-tagged
N171-82Q was PCR amplified from a pCMV-HD-N171-82Q plasmid
(Harper et al., 2005) and cloned into AAV vectors to generate AAV.mHTT.
AAVs were made by University of Iowa Vector Core. Titers (vector genomes/
ml; vg/ml) were assessed by RT-PCR (Rhes: 3 3 1012 vg/ml, RhesS33N:
3 3 1012 vg/ml, caRheb: 3 3 1012 vg/ml, eGFP: 3 3 1012 vg/ml, and mHTT
[N171-82Q]: 3 3 1012 vg/ml).
Injections
The coordinates for striata were 0.86mm rostral to bregma, ± 1.8 mm lateral to
midline, 3.5 mm ventral to the skull surface. N171-82Q mice and WT litter-
mates were injected with AAV.Rhes, AAV.RhesS33N, or saline at 7 weeks of
age. Bilaterally injections were with 5 ml of AAV. For unilateral injection studies,
5 ml of AAV was used. The coordinates for hippocampus were AP, 2.0 mm;
ML, ± 1.5 mm; and DV,2.3 mm relative to bregma; mice were injected unilat-
erally with 1 ml of AAV. For amphetamine-induced rotation tests in WT mice,
3 ml AAV.mHTT was coinjected with either 2 ml AAV.caRheb or 2 ml AAV.eGFP
into the striatum. Injection rates for all studies were 0.2 ml/min. Mice were sacri-
ficed at indicated ages using standard approved methods (Harper et al., 2005;
McBride et al., 2008).
Cell Culture and Transfections
Mutant (Q111) and WT (Q7) striatal cells (Trettel et al., 2000) with full-length
HTT were kindly provided by Dr. Marcy MacDonald. The Q7 and Q111 cells
were grown at 37C in Dulbecco’s modified Eagle’s medium (Sigma Chemical
Co, Saint Louis) supplemented with 10% fetal bovine serum, 1% nonessential
amino acids, 2 mM L-glutamine, and 400 mg/ml G418 (Geneticin; Invitrogen,
Carlsbad). For mTOR inhibition studies, cells were treated with DMSO or
250 nM Torin1 (Tocris, Bristol) for 24 hr.
Mouse Brain Isolation
Mice used for histological analyses were anesthetized with a ketamine/xyla-
zine mix and transcardially perfused with 20 ml of 0.9% cold saline, followed
by 20 ml of 4% paraformaldehyde in 0.1 M PO4 buffer. Brains were removed
and postfixed overnight, and 40-mm thick sections were collected. Mice
used for molecular analyses were perfused with 20 ml of 0.9% cold saline,
and brain was removed and blocked into 1-mm-thick coronal slices. Tissue
punches of striatum were taken using a tissue corer (1.4 mm in diameter), flash
frozen in liquid nitrogen, and stored at 80C until used.
Immunohistochemistry and Quantitation
Floating, 40-mm coronal brain sections were used for histochemistry. The
following primary antibodies were used: DARPP-32, 1:200, Cell Signaling;
Em48 1:200, gift from X. J. Li, Emory University School of Medicine; phos-
pho-S6 antibody, S235/236, 1:300, Cell Signaling. Goat anti-rabbit or goat
anti-mouse biotinylated IgG secondary antibodies were used (1:200; Vector
laboratories) and developed with avidin-biotinylated horseradish peroxidase
complexes (ABC; Vector Labs). In all procedures, deletion of the primary anti-
body served as control. Images were captured on an Olympus BX60 light mi-
croscope and DP70 camera with Olympus DP Controller software (Olympus,
Melville). For each brain, four representative sections were chosen and areas
of 70 DARPP-32 positive MSNs were manually traced under 403 objective
from each hemisphere. The areas of DARPP-32 positive MSN were quantified
by Olympus DP2-BSW software (version 2.1). The average MSN areas of ipsi-
lateral injected sides were compared to contralateral control sides and ex-
pressed as means ± SEM. EM48-positive inclusions were counted by an
experimenter blinded to treatment groups.
Stereology
Striatal volume was calculated using point counting methods with the
Cavalieri estimator of volume (Michel and Cruz-Orive, 1988). Images of
DARPP-32-stained coronal sections (40 mm thick) were captured using an
Olympus BX60 light microscope and DP70 camera with Olympus DP
Controller software (Olympus, Melville). An acetate sheet with a grid pattern
was placed on the image at random angles, and the number of grid inter-
sections overlying the striatum counted. A random systematic set of serial sec-
tions at an interval of 480 mm apart was used. A minimum of 200 points were
counted over five sections. Left and right striatal volumes were determined
independently on the same sections from the point counts by using the formula
VolðobjectÞ =
P
PðobjectÞ,t,aðpÞ, where
P
PðobjectÞ = sum of points overlying the
striatum, t = distance between sections, and Ap = area per point.
EM
Mice were anesthetized and perfused intracardially with saline solution fol-
lowed by 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4).
Brains were removed and postfixed in 2.5% glutaraldehyde, 0.1 M sodium
cacodylate buffer (pH 7.4) for 24 hr. One hundred micrometer coronal sections
were cut with vibratome and fixed in 1% OsO4 in 0.1 M cacodylate for 1 hr,
stained with 1% uranyl acetate, dehydrated, and embedded in Eponate 812.
Ultrathin sections of striatum (80 nm) were examined with a JEOL EX 1200
transmission electron microscope.
Western Blot Analysis
Mouse striata were lysed in RIPA buffer with protease inhibitors (Complete
Mini, Roche Applied Science, Mannheim) and phosphatase inhibitors (Phos-
STOP Phosphatase Inhibitor Cocktail, Roche Applied Science, Mannheim).
Protein concentration was determined by BCA assay (Pierce, Rockford), and
20–30 mg of protein was reduced and ran on SDS-PAGE on 4%–10% acryl-
amide gels and transferred to 0.2 mm Immobilon PVDF membranes (Millipore,
Billerica). Primary antibodies were: DARPP-32, 1:1,000, Cell Signaling; b-actin,
Sigma-Aldrich, 1:5,000; S6,1:1,000, Cell Signaling; phospho-S6, S235/236,
1:1,000, Cell Signaling; 4E-BP1, 1:1,000, Cell Signaling; phospho-4E-
BP1,T37/46, 1:1,000, Cell Signaling; mTOR, 1:1,000, Cell Signaling; Rictor,
1:1,000, Cell Signaling; Raptor,1:1,000, Cell Signaling; CREB, 1:1,000, Cell
Signaling; TORC1, 1:1,000, Cell Signaling; PGC1-a,1:1,000, abcam;
LC3,1:1,000, Novus Biologicals; and Beclin1,1:1,000, Cell Signaling. Second-
ary antibodies were HRP-goat anti-mouse IgG and HRP-goat anti-rabbit IgG
(Cell Signaling). Blots were developed using ECL Plus Western Blotting Detec-
tion System (GE Healthcare, Pittsburg) and exposed to film for images. Protein
quantification was performed using NIH ImageJ software or the VersaDocTM
Imaging System (Biorad) and Quantity One R analysis software. Band den-
sities were normalized to b-actin from the same samples and lanes.
Brain Samples
Coronal sections of human autopsy brain tissues were obtained from unaf-
fected individuals and patients with Vonsattel grade 2, 3, and 4 HD (Dr. Chris-
topher Ross, Johns Hopkins University; NewYork Brain Bank at Columbia Uni-
versity, Alzheimer Disease Research Center, Taub Institute). Tissues were
flash frozen with postmortem intervals ranging from 13 to 49 hr. Caudate/pu-
tamen nuclei were dissected from the frozen tissues placed on an ice-cold
metal stage and homogenized in RIPA buffer with protease inhibitors (Com-
plete Mini, Roche Applied Science, Mannheim) and phosphatase inhibitors
(PhosSTOP Phosphatase Inhibitor Cocktail, Roche Applied Science, Man-
nheim). Lysates were spun at 14,000 3 g for 20 min. The supernatant was
collected for western blot analysis. Additional frozen tissues were processed
for RNA extraction using TRIzol.
Quantitative Real-Time PCR
RNA was isolated from striatal punches using 1 ml of TRIzol. Random-primed
first-strand complementary DNA (cDNA) synthesis was performed using
500 ng total RNA (High Capacity cDNA Reverse Transcription Kit; Applied Bio-
systems, Foster City) per manufacturer’s protocol. Real-time PCR was per-
formed on a sequence detection system (Prism 7900HT, Applied Biosystems)
using SYBR green PCR mix (Invitrogen) or TaqMan 2x Universal Master Mix
(Applied Biosystems). The following Taqman primer/probe sets were obtained
from Applied Biosystem: Rhes (Mm04209172_m1 and Hs04188091_mH),
PGC1-a (Mm01208835_m1), HMGCS1 (Mm01304569_m1), and HDAC4
(Mm01299557_m1). The primer sequences for SYBR green RT PCR are avail-able upon request. Relative gene expression was determined using the DDCT
method, normalizing to b-actin.
Behavioral Tests
Amphetamine-Induced Rotational Assay
Mice were injected with intraperitoneal amphetamine (3 mg/kg; Sigma) and
then placed individually in the center of a square plastic activity chamber
(50 3 50 cm). Mice were allowed to habituate in the chamber for 20 min
before amphetamine induction. Rotational behavior was then recorded for
40 min by a ceiling-mounted video camera. Net rotation was expressed as
number of ipsilateral turns—number of contralateral turns in a 40 min
session.
Accelerating Rotarod
Male N171-82Q mice were tested for baseline motor function at 6 weeks of
age and then at 10, 14, and 18 weeks of age. Before each test, mice were
first habituated on the rotarod for 4 min and rested for 1 hr. The tests were con-
ducted three trials per day (with 30min of rest between trials) for 4 consecutive
days. For each trial, mice were placed on the rod that accelerates from 4 to 40
rotations per min over 4 min and then speed maintained at 40 rpm. Latency to
fall (or if mice hung on for two consecutive rotations without running) was used
as a rating of motor performance. The trials were stopped at 300 s, and mice
remaining on the rotarod at that time were scored as 300 s. Data from the three
trials for each group on each day are presented as means ± SEM. Mice were
always tested in the dark phase of the light/dark cycle. All behavioral experi-
ments were conducted with the experimenter blind to mouse genotypes and
treatments.
Statistical Analyses
Data were analyzed using Student’s t test or one-way ANOVA analysis, fol-
lowed by Tukey’s post hoc analyses to assess for significant differences
between individual groups. All statistical analyses were performed using
GraphPad Prism version 5.0c. Data are expressed as mean ± SEM. In all
cases, p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and can be found with this
article online at http://dx.doi.org/10.1016/j.neuron.2014.12.019.
ACKNOWLEDGMENTS
Supported by NIH grants NS50210 (to B.L.D.) and NS052789-S1 (to L.M.T.
andB.L.D.) and the Roy JCarver Trust (B.L.D.).Wewould like to thankDr. Nan-
dakumar Narayanan for assistance with the amphetamine induced rotational
assay and Dr. Christopher Ross from Johns Hopkins University for patient
brain tissues.
B.L.D. is a founder of Spark Therapeutics, Inc., a gene therapy company.
This work was not supported or done in collaboration with any commercial
entity.
Accepted: December 1, 2014
Published: December 31, 2014
REFERENCES
Baiamonte, B.A., Lee, F.A., Brewer, S.T., Spano, D., and LaHoste, G.J. (2013).
Attenuation of Rhes activity significantly delays the appearance of behavioral
symptoms in a mouse model of Huntington’s disease. PLoS ONE 8, e53606.
Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A.C., Murphy, J.P., Pierre, P.,
and Klann, E. (2012). Genetic removal of p70 S6 kinase 1 corrects molecular,
synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76,
325–337.
Bibb, J.A., Yan, Z., Svenningsson, P., Snyder, G.L., Pieribone, V.A., Horiuchi,
A., Nairn, A.C., Messer, A., and Greengard, P. (2000). Severe deficiencies in
dopamine signaling in presymptomatic Huntington’s disease mice. Proc.
Natl. Acad. Sci. USA 97, 6809–6814.Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc. 313
Cheng, Y., Peng, Q., Hou, Z., Aggarwal, M., Zhang, J., Mori, S., Ross, C.A., and
Duan, W. (2011). Structural MRI detects progressive regional brain atrophy
and neuroprotective effects in N171-82Q Huntington’s disease mouse model.
Neuroimage 56, 1027–1034.
Choi, B.R., Bang, S., Chen, Y., Cheah, J.H., and Kim, S.F. (2013). PKA modu-
lates iron trafficking in the striatum via small GTPase, Rhes. Neuroscience 253,
214–220.
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N., and Krainc, D.
(2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads
to mitochondrial dysfunction and neurodegeneration. Cell 127, 59–69.
Cunningham, J.T., Rodgers, J.T., Arlow, D.H., Vazquez, F., Mootha, V.K., and
Puigserver, P. (2007). mTOR controls mitochondrial oxidative function through
a YY1-PGC-1alpha transcriptional complex. Nature 450, 736–740.
Fox, J.H., Connor, T., Chopra, V., Dorsey, K., Kama, J.A., Bleckmann, D.,
Betschart, C., Hoyer, D., Frentzel, S., Difiglia, M., et al. (2010). The mTOR
kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails
to reduce mutant huntingtin levels in brain and is not neuroprotective in the
R6/2 mouse model of Huntington’s disease. Mol. Neurodegener. 5, 26.
Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang,
L., Kotin, R.M., Paulson, H.L., and Davidson, B.L. (2005). RNA interference im-
proves motor and neuropathological abnormalities in a Huntington’s disease
mouse model. Proc. Natl. Acad. Sci. USA 102, 5820–5825.
Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T., Hughes, G.,
Elliston, L.A., Hartog, C., Goldstein, D.R., Thu, D., et al. (2006). Regional and
cellular gene expression changes in human Huntington’s disease brain.
Hum. Mol. Genet. 15, 965–977.
Humbert, S., Bryson, E.A., Cordelie`res, F.P., Connors, N.C., Datta, S.R.,
Finkbeiner, S., Greenberg, M.E., and Saudou, F. (2002). The IGF-1/Akt
pathway is neuroprotective in Huntington’s disease and involves Huntingtin
phosphorylation by Akt. Dev. Cell 2, 831–837.
Jeong, H., Then, F., Melia, T.J., Jr., Mazzulli, J.R., Cui, L., Savas, J.N., Voisine,
C., Paganetti, P., Tanese, N., Hart, A.C., et al. (2009). Acetylation targets
mutant huntingtin to autophagosomes for degradation. Cell 137, 60–72.
Jia, H., Kast, R.J., Steffan, J.S., and Thomas, E.A. (2012). Selective histone de-
acetylase (HDAC) inhibition imparts beneficial effects in Huntington’s disease
mice: implications for the ubiquitin-proteasomal and autophagy systems.
Hum. Mol. Genet. 21, 5280–5293.
Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C.A., Ye,
K., and Duan, W. (2013). Small-molecule TrkB receptor agonists improve mo-
tor function and extend survival in a mouse model of Huntington’s disease.
Hum. Mol. Genet. 22, 2462–2470.
Johnson, M.A., Rajan, V., Miller, C.E., and Wightman, R.M. (2006). Dopamine
release is severely compromised in the R6/2mousemodel of Huntington’s dis-
ease. J. Neurochem. 97, 737–746.
Karasinska, J.M., and Hayden, M.R. (2011). Cholesterol metabolism in
Huntington disease. Nat. Rev. Neurol. 7, 561–572.
Kim, S.R., Kareva, T., Yarygina, O., Kholodilov, N., and Burke, R.E. (2012). AAV
transduction of dopamine neurons with constitutively active Rheb protects
from neurodegeneration andmediates axon regrowth. Mol. Ther. 20, 275–286.
Kreiner, G., Bierhoff, H., Armentano, M., Rodriguez-Parkitna, J., Sowodniok,
K., Naranjo, J.R., Bonfanti, L., Liss, B., Schu¨tz, G., Grummt, I., and Parlato,
R. (2013). A neuroprotective phase precedes striatal degeneration upon nucle-
olar stress. Cell Death Differ. 20, 1455–1464.
Laplante, M., and Sabatini, D.M. (2012). mTOR signaling in growth control and
disease. Cell 149, 274–293.
Lee, J.H., Sowada, M.J., Boudreau, R.L., Aerts, A.M., Thedens, D.R.,
Nopoulos, P., and Davidson, B.L. (2014). Rhes suppression enhances disease
phenotypes in Huntington’s disease mice. J. Huntingtons Dis. 3, 65–71.
Li, H., Li, S.H., Yu, Z.X., Shelbourne, P., and Li, X.J. (2001). Huntingtin aggre-
gate-associated axonal degeneration is an early pathological event in
Huntington’s disease mice. J. Neurosci. 21, 8473–8481.
Lu, B., and Palacino, J. (2013). A novel human embryonic stem cell-derived
Huntington’s disease neuronal model exhibits mutant huntingtin (mHTT)314 Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc.aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 27,
1820–1829.
Mason, R.P., Casu, M., Butler, N., Breda, C., Campesan, S., Clapp, J., Green,
E.W., Dhulkhed, D., Kyriacou, C.P., and Giorgini, F. (2013). Glutathione perox-
idase activity is neuroprotective in models of Huntington’s disease. Nat.
Genet. 45, 1249–1254.
McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M.,
Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B., et al.
(2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: impli-
cations for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA
105, 5868–5873.
Mealer, R.G., Subramaniam, S., and Snyder, S.H. (2013). Rhes deletion is neu-
roprotective in the 3-nitropropionic acid model of Huntington’s disease.
J. Neurosci. 33, 4206–4210.
Mealer, R.G., Murray, A.J., Shahani, N., Subramaniam, S., and Snyder, S.H.
(2014). Rhes, a striatal-selective protein implicated in Huntington disease,
binds beclin-1 and activates autophagy. J. Biol. Chem. 289, 3547–3554.
Michel, R.P., and Cruz-Orive, L.M. (1988). Application of the Cavalieri principle
and vertical sections method to lung: estimation of volume and pleural surface
area. J. Microsc. 150, 117–136.
Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L.,
Osborne, G.F., Wadel, K., Touller, C., Butler, R., et al. (2013). HDAC4 reduc-
tion: a novel therapeutic strategy to target cytoplasmic huntingtin and amelio-
rate neurodegeneration. PLoS Biol. 11, e1001717.
Milnerwood, A.J., and Raymond, L.A. (2010). Early synaptic pathophysiology
in neurodegeneration: insights from Huntington’s disease. Trends Neurosci.
33, 513–523.
Narita, M., Young, A.R., Arakawa, S., Samarajiwa, S.A., Nakashima, T.,
Yoshida, S., Hong, S., Berry, L.S., Reichelt, S., Ferreira, M., et al. (2011).
Spatial coupling of mTOR and autophagy augments secretory phenotypes.
Science 332, 966–970.
O’Rourke, J.G., Gareau, J.R., Ochaba, J., Song, W., Rasko´, T., Reverter, D.,
Lee, J., Monteys, A.M., Pallos, J., Mee, L., et al. (2013). SUMO-2 and PIAS1
modulate insoluble mutant huntingtin protein accumulation. Cell Rep. 4,
362–375.
Park, K.K., Liu, K., Hu, Y., Smith, P.D., Wang, C., Cai, B., Xu, B., Connolly, L.,
Kramvis, I., Sahin, M., and He, Z. (2008). Promoting axon regeneration in the
adult CNS by modulation of the PTEN/mTOR pathway. Science 322, 963–966.
Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang, S.A.,
Balderas, E., Guertin, D.A., Madden, K.L., Carpenter, A.E., Finck, B.N., and
Sabatini, D.M. (2011). mTOR complex 1 regulates lipin 1 localization to control
the SREBP pathway. Cell 146, 408–420.
Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leevers, S.,
Griffiths, J.R., Chung, Y.L., and Schulze, A. (2008). SREBP activity is regulated
by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8,
224–236.
Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G.,
Scaravilli, F., Easton, D.F., Duden, R., O’Kane, C.J., and Rubinsztein, D.C.
(2004). Inhibition of mTOR induces autophagy and reduces toxicity of polyglut-
amine expansions in fly and mouse models of Huntington disease. Nat. Genet.
36, 585–595.
Roscic, A., Baldo, B., Crochemore, C., Marcellin, D., and Paganetti, P. (2011).
Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin ag-
gregates in a neuronal cell model. J. Neurochem. 119, 398–407.
Saxena, S., Roselli, F., Singh, K., Leptien, K., Julien, J.P., Gros-Louis, F., and
Caroni, P. (2013). Neuroprotection through excitability and mTOR required in
ALS motoneurons to delay disease and extend survival. Neuron 80, 80–96.
Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A.,
Slunt, H.H., Ratovitski, T., Cooper, J.K., Jenkins, N.A., et al. (1999).
Intranuclear inclusions and neuritic aggregates in transgenic mice expressing
a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397–407.
Schulte, J., Sepp, K.J., Wu, C., Hong, P., and Littleton, J.T. (2011). High-con-
tent chemical and RNAi screens for suppressors of neurotoxicity in a
Huntington’s disease model. PLoS ONE 6, e23841.
Seredenina, T., Gokce, O., and Luthi-Carter, R. (2011). Decreased striatal
RGS2 expression is neuroprotective in Huntington’s disease (HD) and exem-
plifies a compensatory aspect of HD-induced gene regulation. PLoS ONE 6,
e22231.
Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho,
R.A., and Cantley, L.C. (2004). The LKB1 tumor suppressor negatively regu-
lates mTOR signaling. Cancer Cell 6, 91–99.
She, P., Zhang, Z.,Marchionini, D., Diaz,W.C., Jetton, T.J., Kimball, S.R., Vary,
T.C., Lang, C.H., and Lynch, C.J. (2011). Molecular characterization of skeletal
muscle atrophy in the R6/2 mouse model of Huntington’s disease. Am. J.
Physiol. Endocrinol. Metab. 301, E49–E61.
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G.R., Zou, Z., Kinch, L.,
Wilkins, A.D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013). Identification of a
candidate therapeutic autophagy-inducing peptide. Nature 494, 201–206.
Simmons, D.A., Belichenko, N.P., Yang, T., Condon, C., Monbureau, M.,
Shamloo, M., Jing, D., Massa, S.M., and Longo, F.M. (2013). A small molecule
TrkB ligand reduces motor impairment and neuropathology in R6/2 and
BACHD mouse models of Huntington’s disease. J. Neurosci. 33, 18712–
18727.
Spano, D., Branchi, I., Rosica, A., Pirro, M.T., Riccio, A., Mithbaokar, P.,
Affuso, A., Arra, C., Campolongo, P., Terracciano, D., et al. (2004). Rhes is
involved in striatal function. Mol. Cell. Biol. 24, 5788–5796.
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Ja¨ger, S., Handschin,
C., Zheng, K., Lin, J., Yang, W., et al. (2006). Suppression of reactive oxygen
species and neurodegeneration by the PGC-1 transcriptional coactivators.
Cell 127, 397–408.
Steffan, J.S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L.C., Slepko,
N., Illes, K., Lukacsovich, T., Zhu, Y.Z., Cattaneo, E., et al. (2004). SUMOmodi-
fication of Huntingtin and Huntington’s disease pathology. Science 304,
100–104.
Subramaniam, S., Sixt, K.M., Barrow, R., and Snyder, S.H. (2009). Rhes, a
striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science
324, 1327–1330.
Subramaniam, S., Napolitano, F., Mealer, R.G., Kim, S., Errico, F., Barrow, R.,
Shahani, N., Tyagi, R., Snyder, S.H., and Usiello, A. (2012). Rhes, a striatal-en-
riched small G protein, mediates mTOR signaling and L-DOPA-induced dyski-
nesia. Nat. Neurosci. 15, 191–193.
Sun, F., Park, K.K., Belin, S., Wang, D., Lu, T., Chen, G., Zhang, K., Yeung, C.,
Feng, G., Yankner, B.A., and He, Z. (2011). Sustained axon regeneration
induced by co-deletion of PTEN and SOCS3. Nature 480, 372–375.
Tabrizi, S.J., Scahill, R.I., Owen, G., Durr, A., Leavitt, B.R., Roos, R.A.,
Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H., et al. (2013).
Predictors of phenotypic progression and disease onset in premanifest
and early-stage Huntington’s disease in the TRACK-HD study: analysis of
36-month observational data. Lancet Neurol. 12, 637–649.
The Huntington’s Disease Collaborative Research Group (1993). A novel gene
containing a trinucleotide repeat that is expanded and unstable on
Huntington’s disease chromosomes. Cell 72, 971–983.
Thompson, L.M., Aiken, C.T., Kaltenbach, L.S., Agrawal, N., Illes, K.,
Khoshnan, A., Martinez-Vincente, M., Arrasate, M., O’Rourke, J.G.,
Khashwji, H., et al. (2009). IKK phosphorylates Huntingtin and targets it for
degradation by the proteasome and lysosome. J. Cell Biol. 187, 1083–1099.Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling,
L.J., Sim, T., Sabatini, D.M., and Gray, N.S. (2009). An ATP-competitive
mammalian target of rapamycin inhibitor reveals rapamycin-resistant func-
tions of mTORC1. J. Biol. Chem. 284, 8023–8032.
Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H.,
Persichetti, F., Cattaneo, E., and MacDonald, M.E. (2000). Dominant pheno-
types produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol.
Genet. 9, 2799–2809.
Troca-Marı´n, J.A., Alves-Sampaio, A., and Montesinos, M.L. (2011). An in-
crease in basal BDNF provokes hyperactivation of the Akt-mammalian target
of rapamycin pathway and deregulation of local dendritic translation in a
mouse model of Down’s syndrome. J. Neurosci. 31, 9445–9455.
Tsai, P.T., Hull, C., Chu, Y., Greene-Colozzi, E., Sadowski, A.R., Leech, J.M.,
Steinberg, J., Crawley, J.N., Regehr, W.G., and Sahin, M. (2012). Autistic-like
behaviour and cerebellar dysfunction in Purkinje cell Tsc1mutant mice. Nature
488, 647–651.
Tsunemi, T., and La Spada, A.R. (2011). PGC-1alpha at the intersection of bio-
energetics regulation and neuron function: From Huntington’s disease to
Parkinson’s disease and beyond. Prog. Neurobiol. 97, 142–151.
Tsunemi, T., Ashe, T.D., Morrison, B.E., Soriano, K.R., Au, J., Roque, R.A.,
Lazarowski, E.R., Damian, V.A., Masliah, E., and La Spada, A.R. (2012).
PGC-1alpha rescues Huntington’s disease proteotoxicity by preventing oxida-
tive stress and promoting TFEB function. Sci. Transl. Med. 4, 142ra197.
Valenza, M., and Cattaneo, E. (2011). Emerging roles for cholesterol in
Huntington’s disease. Trends Neurosci. 34, 474–486.
Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L.,
Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005). Dysfunction of
the cholesterol biosynthetic pathway in Huntington’s disease. J. Neurosci.
25, 9932–9939.
Wong, E., and Cuervo, A.M. (2010). Autophagy gone awry in neurodegenera-
tive diseases. Nat. Neurosci. 13, 805–811.
Xie, Y., Hayden, M.R., and Xu, B. (2010). BDNF overexpression in the forebrain
rescues Huntington’s disease phenotypes in YAC128 mice. J. Neurosci. 30,
14708–14718.
Yamamoto, A., Lucas, J.J., and Hen, R. (2000). Reversal of neuropathology
and motor dysfunction in a conditional model of Huntington’s disease. Cell
101, 57–66.
Yamamoto, A., Cremona, M.L., and Rothman, J.E. (2006). Autophagy-medi-
ated clearance of huntingtin aggregates triggered by the insulin-signaling
pathway. J. Cell Biol. 172, 719–731.
Yu, L., McPhee, C.K., Zheng, L., Mardones, G.A., Rong, Y., Peng, J., Mi, N.,
Zhao, Y., Liu, Z., Wan, F., et al. (2010). Termination of autophagy and reforma-
tion of lysosomes regulated by mTOR. Nature 465, 942–946.
Zhou, X., Lin, D.S., Zheng, F., Sutton, M.A., and Wang, H. (2010). Intracellular
calcium and calmodulin link brain-derived neurotrophic factor to p70S6 kinase
phosphorylation and dendritic protein synthesis. J. Neurosci. Res. 88, 1420–
1432.
Zou, J., Zhou, L., Du, X.X., Ji, Y., Xu, J., Tian, J., Jiang, W., Zou, Y., Yu, S., Gan,
L., et al. (2011). Rheb1 is required for mTORC1 and myelination in postnatal
brain development. Dev. Cell 20, 97–108.
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,
MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R., et al. (2001).
Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease.
Science 293, 493–498.Neuron 85, 303–315, January 21, 2015 ª2015 Elsevier Inc. 315
